Philippines

The Food and Drug Administration of the Philippines (FDA Philippines) is the primary national regulatory authority responsible for the registration, licensing, and post-market surveillance of health products, including pharmaceuticals, medical devices, in vitro diagnostics, and digital health solutions. The agency operates under Republic Act No. 9711, known as the Food and Drug Administration Act of 2009, which expanded its mandate and authority. All health products intended for sale or distribution in the Philippines must obtain a Certificate of Product Registration (CPR) prior to market entry. The registration process involves submission of technical dossiers to the appropriate FDA Center: the Center for Drug Regulation and Research (CDRR) for pharmaceuticals, the Center for Device Regulation, Radiation Health, and Research (CDRRHR) for medical devices and diagnostics, and evolving frameworks for digital health and software as a medical device (SaMD). Risk-based classification systems determine the depth of review required, with higher-risk products subject to more rigorous evaluation.

The FDA Philippines generally accepts dossiers formatted in accordance with the ASEAN Common Technical Dossier (ACTD) and ASEAN Common Technical Requirements (ACTR) standards, reflecting the country's commitments as a member of the ASEAN harmonization framework. Applicants must appoint a local authorized representative or a licensed importer or distributor who holds a valid License to Operate (LTO) issued by the FDA. Foreign manufacturers are required to submit evidence of Good Manufacturing Practice (GMP) compliance, which may be demonstrated through FDA-conducted inspections or recognition of inspections by reference regulatory authorities. Notable recent reforms include the implementation of an online electronic portal for submissions and tracking, accelerated review pathways for pandemic-related or priority health products, and ongoing alignment with ASEAN Mutual Recognition Arrangements (MRAs) to reduce duplicative requirements for products already approved in reference countries.

Public procurement of health products in the Philippines is governed primarily by the Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth), operating under the framework established by Republic Act No. 9184, the Government Procurement Reform Act, and its implementing rules and regulations. The DOH serves as the central authority for national health program procurement, coordinating purchases of essential medicines, vaccines, medical devices, and diagnostics through the Procurement Service of the Department of Budget and Management (PS-DBM) and through Philippine International Trading Corporation (PITC) channels for government-to-government transactions. Procurement is conducted largely through competitive public bidding, with the PhilHealth benefit package and the Philippine National Drug Formulary (PNDF) serving as key reference frameworks for reimbursement eligibility and procurement priority. Regional DOH offices, local government units (LGUs), and government hospitals such as those under the Philippine General Hospital (PGH) system also conduct decentralized procurement within national policy guidelines, creating both a national and sub-national procurement landscape that suppliers must navigate.

The private sector represents a substantial portion of the Philippine health market, encompassing a large network of private hospitals, retail pharmacies, and diagnostic laboratories that procure health products through direct commercial channels and local distributors. Multinational suppliers typically engage through accredited importers and exclusive distributors who hold the necessary FDA License to Operate. Donor-funded procurement plays a meaningful role in specific disease program areas: the Global Fund to Fight AIDS, Tuberculosis and Malaria supports procurement of HIV, TB, and malaria commodities, while UNICEF, USAID, and Gavi contribute to immunization and maternal and child health supply chains. The Universal Health Care Act (Republic Act No. 11223), enacted in 2019, has driven significant reforms to expand PhilHealth coverage and consolidate procurement efficiencies. Local manufacturing preference policies exist under Executive Orders promoting the Philippine generic medicines industry, and the Universally Accessible Cheaper and Quality Medicines Act (Republic Act No. 9502) empowers the DOH to issue compulsory licenses and regulate medicine prices, factors that influence both procurement strategy and market pricing for health products.